Diosmin Hesperidin Blend

The pharmaceutical-grade combination of diosmin and hesperidin in a 9:1 ratio (90 percent diosmin / 10 percent hesperidin), commonly known as Micronized Purified Flavonoid Fraction (MPFF). The combination is the established pharmaceutical standard for chronic venous insufficiency and hemorrhoid management in many European, Asian, and Latin American markets.

Off-white to pale yellow free-flowing powder. Supplied in micronized form (particle size typically less than 2 micrometers) to enhance dissolution and bioavailability.

We supply food-grade and pharmaceutical-grade Diosmin Hesperidin Blend from manufacturers in China holding ISO, Halal, Kosher and other certifications relevant to the product and production. Brand-equivalent grades meeting USP and EP specifications are available.

Common market grades include Standard Diosmin Hesperidin 9:1 (the pharmaceutical workhorse grade), Micronized Diosmin Hesperidin 9:1 (the brand-equivalent bioavailability-enhanced format), Pure Diosmin 90 to 95 percent (the standalone component for custom formulations), and Pure Hesperidin 90 to 95 percent (the standalone component).

Bulk and reduced-MOQ shipments. Batch-level COA covering diosmin content (HPLC), hesperidin content (HPLC), particle-size distribution (micronized grades), residual solvents, heavy metals, and microbiology.

The diosmin-hesperidin combination was developed and clinically characterized by Servier (under the brand name Daflon) in the 1970s and 1980s, becoming the established pharmaceutical standard for chronic venous insufficiency and hemorrhoidal disease in many global markets. The micronized form was introduced to improve oral bioavailability, with particle-size reduction from approximately 35 micrometers to less than 2 micrometers improving dissolution kinetics meaningfully.

Industrial production proceeds by extraction of citrus peel to obtain hesperidin, chemical oxidation of a portion of hesperidin to diosmin, and combination of the two in defined 9:1 ratio. Micronization is performed by air-jet milling under controlled conditions to achieve target particle-size distribution.

Approved as a pharmaceutical product in many European, Asian, and Latin American jurisdictions for chronic venous insufficiency and acute hemorrhoidal episodes. Sold as a dietary supplement in the U.S. and several other markets.

Clinical evidence is among the strongest for any flavonoid product, with multiple large randomized controlled trials supporting efficacy in chronic venous insufficiency (reduced edema, leg pain, leg heaviness) and acute hemorrhoidal episodes (reduced bleeding, pain, prolapse). Recommended in clinical guidelines from several vascular medical societies.

Strategic positioning serves both the pharmaceutical vascular medicine market (the high-unit-value premium segment) and dietary supplement vascular-support applications.

• Pharmaceutical applications: chronic venous insufficiency treatment (the dominant commercial application in regulated markets)
• Hemorrhoid management pharmaceutical products
• Vascular-support dietary supplements in U.S. and other markets without pharmaceutical approval
• Post-surgical edema and recovery support (clinical evidence in dental and vascular surgery)
• Cosmetic skincare: anti-rosacea and capillary-support formulations
• Beauty-from-within supplements positioned for leg-health
• Veterinary applications for vascular and edema support